1. Ethnicity and deprivation negatively impact the access to disease-modifying therapy for relapsing-remitting multiple sclerosis: a retrospective, single-centre study.
- Author
-
Das J, Mallawaarachchi G, Grimshaw J, Jackson T, Talbot P, Sharaf N, Kalatha T, Lord L, Pace A, Mihalova T, Heal C, and Rog D
- Subjects
- Humans, Female, Male, Retrospective Studies, Adult, Middle Aged, Healthcare Disparities ethnology, Ethnicity, Multiple Sclerosis, Relapsing-Remitting drug therapy, Multiple Sclerosis, Relapsing-Remitting ethnology, Health Services Accessibility statistics & numerical data
- Abstract
Background: A growing body of evidence suggests inequitable access to disease-modifying therapies (DMTs) for multiple sclerosis (MS) in publicly funded healthcare systems. This retrospective study examined the impact of ethnicity and deprivation on the access to DMTs., Methods: All adults diagnosed with relapsing-remitting MS between 2010 and 2020 were included. The impact of ethnicity and deprivation on being offered and starting any DMTs and high-efficacy DMTs were measured using binary, multinomial logistic and Cox regression models. These analyses were adjusted for sex, age at diagnosis and year of diagnosis., Results: 164/1648 people with MS (PwMS) were from non-white ethnicities. 461/1648 who were living in the most deprived areas, were less likely to be offered DMTs, with an OR of 0.66 (95% CI 0.47 to 0.93), less likely to start high-efficacy DMTs with an OR of 0.67 (95% CI 0.48 to 0.93) and more likely to experience a delay in starting high-efficacy DMTs with an HR of 0.76 (95% CI 0.63 to 0.92), when also adjusted for ethnicity. Although the offer of DMTs did not depend on ethnicity, PwMS from non-white ethnicities were more likely to decline DMTs, less likely to start any DMTs and high-efficacy DMTs with ORs of 0.60 (95% CI 0.39 to 0.93) and 0.61 (95% CI 0.38 to 0.98), respectively, and more likely to experience a delay in starting DMTs with an HR of 0.79 (95% CI 0.66 to 0.95), when also adjusted for deprivation., Conclusions: In a publicly funded healthcare system, the access to DMTs varied depending on ethnicities and levels of deprivation., Competing Interests: Competing interests: DR reports a relationship with Actelion, Biogen, Celgene, Hikma, Janssen, MedDay, Merck, Mitsubishi, Novartis, Roche, Sanofi, Teva, TG Therapeutics that includes consulting or advisory, funding grants and speaking and lecture fees., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF